1. 国立がん研究センターがん情報サービス「がん登録・統計」（人口動態統計） at <https://ganjoho.jp/reg_stat/statistics/dl/index.html#mortality>
2. 日本泌尿器科学会: 膀胱癌診療ガイドライン2019年版, 第3版(2019年版. 医学図書出版株式会社, 2019
3. Sylvester RJ, Meijden APM Van Der, Oosterlinck W, et al.: Predicting recurrence and progression in individual patients with stage Ta T1 bladder cancer using EORTC risk tables: A combined analysis of 2596 patients from seven EORTC trials. Eur Urol 2006;49:466–77
4. Soukup V, Čapoun O, Cohen D, et al.: Prognostic Performance and Reproducibility of the 1973 and 2004/2016 World Health Organization Grading Classification Systems in Non–muscle-invasive Bladder Cancer: A European Association of Urology Non-muscle Invasive Bladder Cancer Guidelines Panel Systematic Review. Eur Urol 2017;72:801–13
5. Database S. SEER Cancer statistics fact- sheets: bladder cancer. Bethesda, MD: National Cancer
6. Loehrer PJ, Einhorn LH, Elson PJ, et al.: A randomized comparison of cisplatin alone or in combination with methotrexate, vinblastine, and doxorubicin in patients with metastatic urothelial carcinoma: A cooperative group study. J Clin Oncol 1992;10:1066–73
7. Maase H Von der, Hansen SW, Roberts JT, et al.: Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: Results of a large, randomized, multinational, multicenter, phase III study. J Clin Oncol 2000;18:3068–77
8. Goto T, Miyamoto H: Why has the prognosis for muscle-invasive bladder cancer not significantly improved after decades of therapeutic advancements? Expert Rev Anticancer Ther 2020;20:229–31
9. Bellmunt J, Wit R de, Vaughn DJ, et al.: Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma. N Engl J Med 2017;376:1015–26
10. Sonpavde GP, Mariani L, Vullo S Lo, et al.: Impact of the number of cycles of platinum-based first-line chemotherapy for advanced urothelial carcinoma. J Urol 2018;200:1207
11. Dobruch J, Daneshmand S, Fisch M, et al.: Gender and Bladder Cancer: A Collaborative Review of Etiology, Biology, and Outcomes. Eur Urol 2016;69:300–10
12. Miyamoto H, Zheng Y, Izumi K: Nuclear Hormone Receptor Signals as New Therapeutic Targets for Urothelial Carcinoma. Curr Cancer Drug Targets 2012;12:14–22
13. Inoue S, Mizushima T, Ide H, et al.: ATF2 promotes urothelial cancer outgrowth via cooperation with androgen receptor signaling. Endocr Connect 2018;7:1397–408
14. Jia M, Dahlman-Wright K, Gustafsson J-Å: Estrogen receptor alpha and beta in health and disease. Best Pract Res Clin Endocrinol Metab 2015;29:557–68
15. Goto T, Miyamoto H: The Role of Estrogen Receptors in Urothelial Cancer. Front. Endclinol. 2021;12:1–10
16. Hsu I, Yeh C-R, Slavin S, et al.: Estrogen Receptor Alpha Prevents Bladder Cancer Development via INPP4B inhibited Akt Pathway in vitro and in vivo. Oncotarget 2014;5:7917–35
17. Hsu I, Chuang K-L, Slavin S, et al.: Suppression of ERβ signaling via ERβ knockout or antagonist protects against bladder cancer development. Carcinogenesis 2014;35:651–61
18. Ide H, Inoue S, Miyamoto H: Histopathological and prognostic significance of the expression of sex hormone receptors in bladder cancer: A meta-analysis of immunohistochemical studies. PLoS One Edited by Real FX. 2017;12:e0174746
19. Rao Q, Chen Y, Yeh C-R, et al.: Recruited mast cells in the tumor microenvironment enhance bladder cancer metastasis via modulation of ERβ/CCL2/CCR2 EMT/MMP9 signals. Oncotarget 2016;7:7842–55
20. Ou Z, Wang Y, Chen J, et al.: Estrogen receptor β promotes bladder cancer growth and invasion via alteration of miR-92a/DAB2IP signals. Exp Mol Med 2018;50:1–11
21. Tao L, Qiu J, Slavin S, et al.: Recruited T cells promote the bladder cancer metastasis via up-regulation of the estrogen receptor β/IL-1/c-MET signals. Cancer Lett 2018;430:215–23
22. Brierley J.D., Gospodarowicz M.K., UICC: TNM 8 th edition due December 2016. Union Int Cancer Control 2016;
23. 日本泌尿器科学会・日本病理学会・日本医学放射線学会: 泌尿器科・病理・放射線科 腎盂・尿管・膀胱癌取扱い規約, 第1版. 金原出版株式会社, 2011
24. Remmele W, Schicketanz KH: Immunohistochemical determination of estrogen and progesterone receptor content in human breast cancer: Computer-assisted image analysis (QIC score) vs. subjective grading (IRS). Pathol Res Pract 1993;189:862–6
25. Kanda Y: Investigation of the freely available easy-to-use software “EZR” for medical statistics. Bone Marrow Transplant 2013;48:452–8
26. Izumi K, Li Y, Ishiguro H, et al.: Expression of UDP-glucuronosyltransferase 1A in bladder cancer: Association with prognosis and regulation by estrogen. Mol Carcinog 2014;53:314–24
27. Kashiwagi E, Inoue S, Mizushima T, et al.: Prostaglandin receptors induce urothelial tumourigenesis as well as bladder cancer progression and cisplatin resistance presumably via modulating PTEN expression. Br J Cancer 2018;118:213–23
28. Y T, X W, Y W, et al.: Wnt/beta-catenin signaling regulates cancer stem cells in lung cancer A549 cells. Biochem Biophys Res Commun 2010;392:373–9
29. Zhao H, Wei W, Sun Y, et al.: Interference with the expression of β-catenin reverses cisplatin resistance in A2780/DDP cells and inhibits the progression of ovarian cancer in mouse model. DNA Cell Biol 2015;34:55–62
30. Li Y, Zheng Y, Izumi K, et al.: Androgen activates β-catenin signaling in bladder cancer cells. Endocr Relat Cancer 2013;20:293–304
31. Zhang X, Tang N, Hadden TJ, et al.: Akt, FoxO and regulation of apoptosis. Biochim Biophys Acta - Mol Cell Res 2011;1813:1978–86
32. Ide H, Mizushima T, Jiang G, et al.: FOXO1 as a tumor suppressor inactivated via AR/ERβ signals in urothelial cells. Endocr Relat Cancer 2020;27:231–44
33. Nguyen DP, O’Malley P, Hussein Al Awamlh B Al, et al.: Association of Aromatase With Bladder Cancer Stage and Long-Term Survival: New Insights Into the Hormonal Paradigm in Bladder Cancer. Clin Genitourin Cancer 2017;15:256-262.e1
34. Kashiwagi E, Ide H, Inoue S, et al.: Androgen receptor activity modulates responses to cisplatin treatment in bladder cancer. Oncotarget 2016;7:49169– 79
35. Teng J, Wang ZY, Jarrard DF, et al.: Roles of estrogen receptor α and β in modulating urothelial cell proliferation. Endocr Relat Cancer 2008;15:351–64
36. Coussens LM, Werb Z: Inflammation and cancer. Nature 2002;420:860–7
37. Ristimäki A, Nieminen O, Saukkonen K, et al.: Expression of cyclooxygenase-2 in human transitional cell carcinoma of the urinary bladder. Am J Pathol 2001;158:849–53
38. Ho C-C, Ling Y-C, Chang LW, et al.: 17-Beta estradiol and hydroxyestradiols interact via the NF-kappa B pathway to elevate cyclooxygenase 2 expression and prostaglandin E2 secretion in human bronchial epithelial cells. Toxicol Sci 2008;104:294–302
39. Son HJ, Kim N, Song C-H, et al.: 17β-Estradiol reduces inflammation and modulates antioxidant enzymes in colonic epithelial cells. Korean J Intern Med 2020;35:310–9
40. Lai T-Y, Chen L-M, Lin J-Y, et al.: 17beta-estradiol inhibits prostaglandin E2- induced COX-2 expressions and cell migration by suppressing Akt and ERK1/2 signaling pathways in human LoVo colon cancer cells. Mol Cell Biochem 2010;342:63–70
41. Grubisha MJ, Cifuentes ME, Hammes SR, et al.: A local paracrine and endocrine network involving TGFβ, Cox-2, ROS, and estrogen receptor β influences reactive stromal cell regulation of prostate cancer cell motility. Mol Endocrinol 2012;26:940–54
42. Kelly JD, Tan WS, Porta N, et al.: BOXIT-A Randomised Phase III Placebo- controlled Trial Evaluating the Addition of Celecoxib to Standard Treatment of Transitional Cell Carcinoma of the Bladder (CRUK/07/004). Eur Urol 2019;75:593–601
43. Sonpavde G, Okuno N, Weiss H, et al.: Efficacy of Selective Estrogen Receptor Modulators in Nude Mice Bearing Human Transitional Cell Carcinoma. Urology 2007;69:1221–6
44. Evaluation the Treatment of Tamoxifen of Low/Intermediate Risk Bladder Tumors at <https://clinicaltrials.gov/ct2/show/results/NCT02197897>
45. Valenta T, Hausmann G, Basler K: The many faces and functions of β-catenin. EMBO J 2012;31:2714–36
46. X C, C J, C J, et al.: MicroRNA-374a Inhibits Aggressive Tumor Biological Behavior in Bladder Carcinoma by Suppressing Wnt/β-Catenin Signaling. Cell Physiol Biochem 2018;48:815–26
47. W M, J E, R S, et al.: MicroRNA Biomarkers for Patients With Muscle-Invasive Bladder Cancer Undergoing Selective Bladder-Sparing Trimodality Treatment. Int J Radiat Oncol Biol Phys 2019;104:197–206
48. EK S, Z Z, J H, et al.: Research resource: global identification of estrogen receptor β target genes in triple negative breast cancer cells. Mol Endocrinol 2013;27:1762–75
49. Hsu H-H, Cheng S-F, Wu C-C, et al.: Apoptotic effects of over-expressed estrogen receptor-beta on LoVo colon cancer cell is mediated by p53 signalings in a ligand-dependent manner. Chin J Physiol 2006;49:110–6
50. Zhang Y, Yin C, Zhou X, et al.: Silencing of estrogen receptor β promotes the invasion and migration of osteosarcoma cells through activating Wnt signaling pathway. Onco Targets Ther 2019;12:6779–88
51. Dey P, Jonsson P, Hartman J, et al.: Estrogen receptors β1 and β2 have opposing roles in regulating proliferation and bone metastasis genes in the prostate cancer cell line PC3. Mol Endocrinol 2012;26:1991–2003
52. Lombardi APG, Pisolato R, Vicente CM, et al.: Estrogen receptor beta (ERβ) mediates expression of β-catenin and proliferation in prostate cancer cell line PC-3. Mol Cell Endocrinol 2016;430:12–24
53. Motawi TK, Darwish HA, Diab I, et al.: Combinatorial strategy of epigenetic and hormonal therapies: A novel promising approach for treating advanced prostate cancer. Life Sci 2018;198:71–8
54. Mao X, Zhang L, Huang B, et al.: Mir-135a enhances cellular proliferation through post-transcriptionally regulating PHLPP2 and FOXO1 in human bladder cancer. J Transl Med 2015;13:86
55. J L, A F-T, N J, et al.: FOXO1 down-regulation is associated with worse outcome in bladder cancer and adds significant prognostic information to p53 overexpression. Hum Pathol 2017;62:222–31
56. YK L, P M, S H, et al.: Estrogen receptor (ER)-beta isoforms: a key to understanding ER-beta signaling. Proc Natl Acad Sci U S A 2006;103:13162–7
論文の公開元へ
